Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Clinical trial NCT02441686 · COMPLETED
Trial details
- NCT number
- NCT02441686
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-01
- Primary completion
- 2021-12-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.